Lauric acid leelamide is the lauric (C-12) amide analog of leelamine. Leelamine has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, exhibiting 20% displacement of [3H]-CP55940 at a concentration of 10 μM. Leelamine inhibits pyruvate dehydrogenase kinase (PDHK) with an IC50 value of 9.5 μM. Derivatives of leelamine exhibit anti-inflammatory activity and show moderate inhibition of phospholipase A2 activity from a variety of sources. There are no published studies of the pharmacological properties of lauric acid leelamide.
